Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Pylobactell er større end risiciene, når lægemidlet anvendes til in vivo- diagnosticering af gastroduodenal H. pylori - infektion.
The Committee for Medicinal Products for Human Use (CHMP) decided that Pylobactell’ s benefits are greater than its risks for the in vivo diagnosis of gastroduodenal H. pylori infection.